Kornimate/medical-research-clean huggingface dataset:
imaging the dopamine systems in bulimia nervosa

Conditions: Eating Disorders

Summary: this study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.


Eligibility criteria:
inclusion criteria: participants with bn: * meets dsm-iv criteria for bn * sufficiently medically and psychiatrically stable to participate in research health control participants: * no current or past psychiatric illness * between 80% and 120% of ideal body weight exclusion criteria: all participants: * current use of psychotropic medication such as anti psychotics or antidepressants * pregnant or breastfeeding * history of substance abuse * significant medical illness * high blood pressure (resting systolic blood pressure greater than 150mmhg and diastolic blood pressure greater that 90 mmhg) * current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by dsm-iv * metal implants or paramagnetic objects contained within the body that may interfere with the mri scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines * exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry * previous adverse reaction to psycho stimulants

Keywords: bulimia nervosa pet imaging dopamine
injections of svf in ankle osteoarthritis

Conditions: Ankle Osteoarthritis

Summary: the aim of this pilot study is to analyze the effect of svf injection produced by adipose tissue processing, in terms of clinical improvement, in patients with moderate to severe (stage 1-3) ankle osteoarthritis. evaluation will be performed by administering pre-operative and post-operative clinical assessment questionnaires. patients will be followed-up with a pre-operative evaluation and post-operative evaluations at 30 days, 3-6-12, and 24 months after application.

30 patients with moderate to severe ankle osteoarthritis (grade 1-3 according to giannini's classification) will be included in this pilot study, in which patients will be treated with single injection of stromal vascular fraction - svf ,obtained by processing the patient's abdominal adipose tissue. all patients will be examined with a baseline clinical visit. for obtaining svf, will be carried out a routinely performed procedure aimed at obtaining a small amount of adipose tissue from all patients. subsequently, patients will be followed up with clinical evaluation at 1, 3, 6, 12 and 24 months.

Eligibility criteria:
inclusion criteria: 1. patients suffering from moderate to severe unilateral ankle arthrosis (grade 1-3 according to giannini's classification); 2. patients who gave written informed consent to participate in the study; 3. .patients with mri examination showing absence of osteochondral lesion; 4. patients who have given their willingness to come to the institute for follow-up visits exclusion criteria: 1. patients with bmi\>30 kg/m2 2. patients with rheumatoid arthritis 3. patients with chronic inflammatory joint disease; 4. patients with acute or chronic infections; 5. patients with pre-existing abnormalities of gait kinematics (amputations, neuro-muscular diseases, poliomyelitis, hip dysplasia); 6. patients with severe knee arthrosis (kellgren-lawrence\>3); 7. patients with ankle deformities greater than 8°; 8. patients with pain on other joints of the foot; 9. patients with severe postural instability; 10. patients with cognitive deficits; 11. patients with concomitant neurological pathologies

Keywords: svf ankle ankle osteoarthritis stromal vascular fraction injection treatment adscs pilot study adipose derived stromal cell's
role of ivermectin nanosuspension as nasal spray in treatment of persistant post covid19 anosmia

Conditions: Anosmia

Summary: ivermectin is fda approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

ivermectin is fda approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Eligibility criteria:
inclusion criteria: * post covid19 anosmia * negative swab test for covid19 exclusion criteria: * other types of anosmia , * no local or central other causes of anosmia * still active covid 19 pateints ( positive swab test )
second malignant neoplasms after childhood all therapy

Conditions: Acute Lymphoblastic Leukemia

Summary: development of a second neoplasm (smn) during or after therapy for childhood acute lymphoblastic leukemia (all) is a rare event generally associated with a poor prognosis. in this international study we analyze subtypes of smn in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.

to explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical, biological, and cytogenetic characteristics (myeloid neoplasias only) as well as outcome. furthermore, we will register the clinical, biological, and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given.

Eligibility criteria:
inclusion criteria: * diagnosed with childhood acute lymphoblastic leukemia * diagnosis of second cancer before december 31st 2007 exclusion criteria: * uncertainty if the second cancer has emerged from the same original leukemic clone

Keywords: acute lymphoblastic leukemia ponte-di-legno consortium second cancer survival
paxlovid for treatment of long covid

Conditions: Post-acute Sequelae of SARS-CoV-2 Infection; Long COVID

Summary: the purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of long covid. participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days. this study uses the term post-acute sequelae of sars-cov-2 (pasc), which is another name for "long covid."

an exploratory sub-study will investigate the correlation of physical activity and biometric parameters from digital wearable devices with the subjective symptom severity and other patient-reported outcomes in the main study. all participants with iphone 6s plus or newer will be offered an opportunity to opt-in to this sub-study. an apple watch and bluetooth-enabled blood pressure monitor will be provided to participants and data will be collected for the duration of the main study to track participants' physiological and behavioral trends in the paxlovid versus placebo groups.

Eligibility criteria:
inclusion criteria: * normal or near-normal kidney function * history of confirmed covid-19 infection that preceded the post-covid symptoms * post-covid-19 symptoms persisting greater than three months * at least 2 post-covid symptoms of moderate or severe intensity (fatigue, brain fog, shortness of breath, body aches, gastrointestinal symptoms, or cardiovascular symptoms) * willing to report all vaccinations * women of childbearing potential or men whose partners may become pregnant must use acceptable method of contraception during the treatment period and for 28 days after the last dose of the study drug * willing and able to adhere to study procedures and available for the duration of the study exclusion criteria: * suspected or confirmed pregnancy or breastfeeding * severe liver disease * prior use of study drug or other covid treatment within 30 days * hypersensitivity or other contraindication to any components of the study drug * current or expected use of any medication dependent on or inducer of cyp3a4 * current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held (period as determined necessary by investigators) * hiv infection with viral load \>50 copies/ml * suspected or confirmed active covid infection within 30 days * history of covid vaccine within 28 days prior to enrollment, or other vaccine (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until the primary endpoint has been met (10 weeks) * other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators * current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device * inability to provide informed consent * currently hospitalized
wrist arthroscopy study

Conditions: Wrist Arthropathy

Summary: the purpose of this study is to evaluate the diagnostic efficacy of arthrex nanoscope compared to conventional arthroscopic instruments. patients with wrist pathology who are indicated for an arthroscopic procedure will be enrolled pre-operatively after a thorough discussion of the study aims, risks, and benefits. at the time of surgery, under standard conditions, using standard wrist arthroscopy portals, a diagnostic arthroscopy will be performed with the arthrex nanoscope. the diagnostic arthroscopy will be performed in a stepwise manner for consistency with notation of pathology and intended intervention. the diagnostic arthroscopy will then be performed with the standard arthroscopic equipment, again noting pathology and final intervention. post-operatively, diagnostic accuracy, incidence of change in intervention, and surgeon rated ease of use and confidence will be determined.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years. 2. wrist pathology based on clinical examination/imaging studies undergoing wrist arthroscopy for further evaluation/treatment. 3. willingness to participate in the study exclusion criteria: * 1. age \< 18 years.
clinical evaluation of lava digital veneer system (dvs) crowns

Conditions: Decay

Summary: study aim is to compare lava computer aided design / computer aided milling computer aided machining (cad/cam)crowns that are veneered (covered) with porcelain that has been milled using cad/cam, with similar cad/cam lava crowns that have been veneered with a hand fabricated porcelain covering.

veneers will be randomly allocated to study crowns. study crowns will be evaluated over three years. the test porcelain veneer is cad/cam milled as a veneer shell that is then fused to the cad/cam milled lava crown to make the final crown to be cemented in the patient's mouth. this may be a more predictable technique in the fabrication of lava crowns than current conventional methods.

Eligibility criteria:
inclusion criteria: * over 18 years of age. * have at least one decayed back tooth in need of a crown * study tooth to be an upper or lower premolar or molar tooth/ teeth * study tooth to be vital and asymptomatic at start of study exclusion criteria: * teeth which are non vital, have had root canal treatment * teeth which are pulp capped * sensitive teeth * significant untreated dental disease including periodontitis and rampant decay * pregnant or lactating women * patients with allergies to any of the materials to be used in the study * unable to attend the recall appointments

Keywords: crowns posterior teeth cad cam crowns digital veneer system lava clinical
perioperative normothermia: temperature and prewarming methods

Conditions: Hypothermia

Summary: the present proposal intends to determine the effect of prewarming on body temperature in the perioperative period of patients submitted to digestive system surgeries and to evaluate a perioperative "zero-heat-flux cutaneous" body temperature thermometer in comparison to the standard care (temporal thermometer in the preoperative and postoperative, and esophageal in the intraoperative period). this is a randomized clinical trial consisting of three groups, namely: preoperative warming of patients with blanket and cotton sheet (control); preoperative warming with forced air warming system for 20 minutes (intervention 1), and participants submitted to preoperative warming with a forced air warming system for 30 minutes (intervention 2).

the present proposal intends to determine the effect of prewarming on body temperature in the perioperative period of patients submitted to digestive system surgeries and to evaluate a perioperative "zero-heat-flux cutaneous" body temperature thermometer in comparison to the standard care (temporal thermometer in the preoperative and postoperative, and esophageal in the intraoperative period). this is a randomized clinical trial consisting of three groups, namely: preoperative warming of patients with blanket and cotton sheet (control); preoperative warming with forced air warming system for 20 minutes (intervention 1), and participants submitted to preoperative warming with a forced air warming system for 30 minutes (intervention 2)

Eligibility criteria:
inclusion criteria: * patients aged 18 years and over at the time of data collection * patients submitted to elective oncological surgery of the digestive, curative or palliative system, with anesthesia duration of at least one hour exclusion criteria: * subjects with body temperature equal to or greater than 38 ºc at the time of admission to the surgical center * patients submitted to video laparoscopic or minimally invasive surgeries

Keywords: nursing hypothermia perioperative nursing
clinical impact of fluoroquinolone resistance in bacteremia caused by gram-negative bacilli of urinary tract origin

Conditions: Urinary Tract Infection; Fluoroquinolone; Bacteremia

Summary: the information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially escherichia coli. the current idsa guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. however, over use of this empiric regimen could result in in appropriate treatment of bacteremia.

the following information will be collected: age, sex, occupation, hospital location at the time of positive culture (er, medical ward, icu etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. we will collect information retrospectively.

Eligibility criteria:
inclusion criteria: * clinical information is collected by chart review of "case" and "control" patients. a "case" patient is defined as follows: * one or more blood cultures are positive for gram-negative bacteria. * the same organism is recovered in urine culture within a 48-hour period. * the organism is ciprofloxacin resistant. * a "control" patient is defined as follows: * one or more blood cultures are positive for gram-negative bacteria. * the same organism is recovered in urine culture within a 48-hour period. * the organism is ciprofloxacin susceptible. exclusion criteria: * negative culture

Keywords: bacteremia urinary tract infections fluoroquinolone
control of fluid balance guided by body composition monitoring in patients on peritoneal dialysis

Conditions: Peritoneal Dialysis, Continuous Ambulatory

Summary: bioimpedance-guided fluid management in peritoneal dialysis patients may provide better protection of residual renal function over 1 year period, compared with management guided by clinical information alone - such as blood pressure, body weight, and physician's physical examination.


Eligibility criteria:
inclusion criteria: * age bwten 20 and 75 * peritoneal dialysis \> 4 weeks duration * written consent * daily urine output \> 500 ml exclusion criteria: * subjects who are contraindicated to the bioimpedance measurement (pacemaker insertion state, defibrillator state, amputee, prosthesis, metal implants) * pregnant women * subjects who are expected to discontinue peritoneal dialysis with one year * mixed dialysis modality (peritoneal + hemodialysis) * hypoalbuminemic subjects (serum albumin \< 3.3 g/dl) * high blood pressure (\> 160/100 mmhg despite antihypertensive medications) * severe heart failure (nyha fc iii, or iv)

Keywords: fluid edema
comparing the analgesic effect of intravenous acetaminophen and morphine on patients with renal colic pain reffering to the emergency department: a randomized controlled trial

Conditions: Renal Colic

Summary: kidney stone is one of the most common diseases in every human society and also iran. what is normally used to treat renal colic pain is intravenous opioid with a variety of side effects including hypotension, respiratory depression and apnea, nausea and vomiting. regarding less complications of intravenous acetaminophen, we aimed to compare it with intravenous morphine in management of renal colic pain.

kidney stone is one of the common diseases of human society which is demonstrated in the form of renal colic. evidences indicate that renal colic is one of the mot painful conditions that require urgent pain relief treatment. patients suffering from renal colic do not usually recover from pain by using oral pain killers or rectal suppositories. hence, a considerable percentage of these patients are admitted to the emergency department. a bothering and sharp pain is the most common characteristics of renal colic pain that wakes the patient up in the middle of the night. to achieve more relief, patients somehow take unusual positions such as squatting. what are normally used as pain relievers in emergency department are non-steroidal anti-inflammatory drugs (nsaids) and intravenous opioids. however, both of these classes of drugs have many side effects. another point in this regard which is worthy to be mentioned is that some patients with renal colic complaint are drug addicted, so we have to administer higher dosage of analgesic drugs. according to the statistics provided by the us national library website, the prevalence of kidney stones around the world in 2005 has been averagely around 140.1% which is considerable. this issue suggests more attention to the field of prevention and treatment. according to the statistics of kidney stones incidence in iran, 2.4 out of every 1000 people suffer from this pathologic condition whereas it differs from 0.5 to 2 in every 1000 ones in other countries. intravenous acetaminophen has been imported to our country and introduced with the brand of apotel. in this regard, we decided to compare the effect of intravenous acetaminophen and morphine on renal colic pain.

Eligibility criteria:
inclusion criteria: * aged 15 to 80 years * weight of 60 to 80 kilograms * known case of renal colic based on physical examination and ultrasonography exclusion criteria: * addiction * allergic to opioids and acetaminophen * receiving any types of analgesic drugs within previous 6 hours * known cases of kidney transplantation * patients with known heart failure * patients with known liver failure * patients with known respiratory failure * patients with known renal failure * cases of blindness and physical disabilities not able to communicate

Keywords: morphine, acetaminophen, renal colic, emergency treatment
minimum dose ct post lung biopsy

Conditions: Lung Cancer

Summary: the aim is to evaluate whether minimum dose ct (mndct) is useful in the management of patients post lung biopsy

patients post lung biopsy have a chest x-ray (cxr) and a mndct post lung biopsy. both studies are compared for the detection of a pneumothorax

Eligibility criteria:
inclusion criteria: * all patients having a lung biopsy exclusion criteria: * none
apoe genotyping analysis in patients with suspected non-haemorrhagic amyloid angiopathy

Conditions: Amyloid Angiopathy

Summary: ischaemic microangiopathic features have recently been incorporated into the criteria for cerebral amyloid angiopathy (caa). apoe genotyping (presence of the e4 allele) is routinely used to help determine the aetiology of a haemorrhagic microangiopathy found on mri. chronic ischaemic disease in caa is characterised by the presence of : * multispot pattern on the flair sequence * severe periventricular flair hypersignals with posterior predominance the main aim of this study was therefore to analyse the frequency of the presence of one (or two) e4 allele(s) on apoe genotyping in patients with suspected caa based on ischaemic mri involvement with a typical radiological pattern.


Eligibility criteria:
inclusion criteria: * patients with ischaemic stroke (from causes other than caa, as caa is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on mri that may suggest associated caa. * patients treated at nîmes university hospital exclusion criteria: * patient refusing to participate

Keywords: cerebral amyloid angiopathy
parent-delivered massage for children with autism - ages 6 to 11

Conditions: Autism

Summary: through funding from the u.s. maternal and child health bureau, teaching research institute at western oregon university (wou) will be conducting research on the effect of a parent-delivered massage program on measures of autism and general development in children ages 6 to 11 with autism. families will participate in an initial training, and receive 24 sessions of ongoing support and training from a trained therapist over the first nine months.

children will be randomly divided into treatment groups and wait-list control groups. the control groups begin treatment five months after the treatment groups begin. all children will be tested on three occasions in the first year: prior to beginning treatment, and five and twelve months later. results will be shared with parents at the end of each year. testers will remain blinded as to which group is currently receiving treatment. there is no cost to parents for participation in this research study. families meeting the eligibility criteria will be accepted into the study on a first-come, first-served basis.

Eligibility criteria:
inclusion criteria: * have a medical and/or educational diagnosis of autism * be between the age of 6 and 11 * parents willing to attend the parent training session and transport the child to treatment sessions with trained staff 20 times in the first five months * parents willing to give the fifteen-minute massage daily * parents willing not to start any new interventions unless medically necessary exclusion criteria: * taking psychoactive medication or pharmaceutical chelation therapy * additional chronic disability (for example, cerebral palsy or uncontrolled seizures) * receiving more than fifteen hours per week of intensive behavioral treatment for autism (e.g. applied behavior analysis therapy)

Keywords: massage effectiveness autism parent stress